DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Huntington National Bank

Huntington National Bank raised its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 94.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 2,748 shares of the medical device company’s stock after buying an additional 1,335 shares during the period. Huntington National Bank’s holdings in DexCom were worth $214,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Public Sector Pension Investment Board boosted its stake in DexCom by 5.9% during the third quarter. Public Sector Pension Investment Board now owns 17,842 shares of the medical device company’s stock valued at $1,196,000 after buying an additional 1,000 shares in the last quarter. Captrust Financial Advisors lifted its holdings in DexCom by 4.6% in the 3rd quarter. Captrust Financial Advisors now owns 23,051 shares of the medical device company’s stock valued at $1,545,000 after acquiring an additional 1,022 shares during the last quarter. Benjamin Edwards Inc. bought a new position in shares of DexCom during the 3rd quarter valued at about $652,000. Jacobs Levy Equity Management Inc. grew its stake in shares of DexCom by 660.5% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 34,609 shares of the medical device company’s stock worth $2,320,000 after purchasing an additional 30,058 shares during the last quarter. Finally, Investment Management Corp of Ontario grew its stake in shares of DexCom by 51.8% in the 3rd quarter. Investment Management Corp of Ontario now owns 13,194 shares of the medical device company’s stock worth $885,000 after purchasing an additional 4,500 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 105,009 shares of company stock worth $8,044,178 in the last three months. 0.30% of the stock is owned by insiders.

DexCom Stock Down 3.2 %

DexCom stock opened at $59.83 on Friday. The firm’s 50 day moving average price is $80.14 and its two-hundred day moving average price is $76.92. The firm has a market cap of $23.46 billion, a PE ratio of 41.84, a P/E/G ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $141.99. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on DXCM shares. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and increased their target price for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Citigroup raised their price objective on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Morgan Stanley lifted their target price on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and upped their target price for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Finally, Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Five research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.